Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Scorpius Holdings Inc SCPX

Scorpius Holdings, Inc. is a contract development and manufacturing organization (CDMO) that provides process development and biomanufacturing services to support the biomanufacturing needs of third parties who use its biomanufacturing capacity as a fee-for-service model through its subsidiary, Scorpius Biomanufacturing, Inc. The Company couples Current Good Manufacturing Practices (CGMP) biomanufacturing and quality control knowledge with capabilities in immunoassays, molecular assays, and bioanalytical methods to support cell- and gene-based therapies as well as large molecule biologics using American-made equipment, reagents, and materials. It offers an array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. The Company's CDMO service offerings also include enhanced microbial and mammalian development and manufacturing services.


NYSEAM:SCPX - Post by User

Post by ghayeson Nov 08, 2021 3:06pm
447 Views
Post# 34101464

anyone else following HTBX ?

anyone else following HTBX ?Anyone else got any insights into HTBX ? had a couple of run ups a year ago and 6 months ago, since then, it is just dithering around the low $5 range. I  look at their most advanced product pipleline item, HS110 a treatment for non-small cell lung cancer - and I see that the study isn't due to be completed until August 2022.A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov 
That is a while to wait.
Anyone give me some other reasons to get in at $5 now?
Otherwise I just see this drifting down to.. $5, $3, $2...?
Seems to be a good complany with some good products, but when are they going to deliver a breakthrough?  GLTA...
<< Previous
Bullboard Posts